Critical Illness Neuromyopathy

ICU-acquired weakness (ICUAW) is one of the most common neuromuscular complications encountered in critically ill patients, affecting 25–50% of those requiring mechanical ventilation for more than 7 days. The condition encompasses three overlapping entities: critical illness polyneuropathy (CIP), critical illness myopathy (CIM), and critical illness neuromyopathy (CINM), in which features of both neuropathy and myopathy coexist. ICUAW prolongs mechanical ventilation, increases ICU and hospital length of stay, impairs long-term functional recovery, and independently increases mortality. Recognizing risk factors, understanding the distinct pathophysiologic mechanisms, and applying targeted prevention strategies are essential for neurologists and intensivists managing these patients.

Definition & Terminology

The terminology surrounding weakness acquired in the ICU has evolved considerably. ICU-acquired weakness (ICUAW) is the overarching clinical term for clinically detected weakness in critically ill patients without an identifiable cause other than the critical illness itself. Within this umbrella, three pathophysiologically distinct but frequently overlapping entities are recognized:

• Critical illness polyneuropathy (CIP): A diffuse, symmetric, length-dependent axonal sensorimotor polyneuropathy occurring in the setting of critical illness, primarily affecting motor axons
• Critical illness myopathy (CIM): A primary myopathy characterized by loss of thick (myosin) filaments, muscle membrane inexcitability, and type 2 fiber atrophy, occurring independently of denervation
• Critical illness neuromyopathy (CINM): The coexistence of CIP and CIM in the same patient — this overlap is found in the majority of electrophysiologically studied cases and is the most common presentation

These conditions must be distinguished from other causes of ICU weakness such as prolonged neuromuscular blockade, Guillain-Barré syndrome, and pre-existing neuromuscular disorders.

Epidemiology & Risk Factors

The reported incidence of ICUAW varies widely based on diagnostic criteria, patient population, and timing of assessment. In general medical-surgical ICU populations, ICUAW affects approximately 25–30% of patients ventilated for ≥7 days. In patients with sepsis, systemic inflammatory response syndrome (SIRS), or MODS, the incidence rises to 50–100%. CIM is more common than pure CIP when electrodiagnostic studies are performed, and CINM overlap is the most frequently identified pattern.

Pathophysiology

Critical Illness Polyneuropathy (CIP)

CIP is a primary axonal neuropathy driven by systemic inflammation and microvascular injury. The proposed mechanisms include:

• Microvascular damage: Inflammatory cytokines (TNF-α, IL-1β, IL-6) increase endothelial permeability in the vasa nervorum, causing endoneurial edema and ischemia of peripheral nerve axons
• Channelopathy: Acquired sodium channelopathy leads to impaired nerve impulse propagation and axonal inexcitability without structural axonal loss in early stages
• Metabolic derangements: Hyperglycemia-induced mitochondrial dysfunction, oxidative stress, and impaired axonal transport contribute to axonal degeneration
• Bioenergetic failure: Mitochondrial dysfunction from sepsis-related metabolic acidosis and hypoxia reduces ATP availability for axonal membrane potential maintenance

Critical Illness Myopathy (CIM)

CIM involves direct skeletal muscle injury through multiple converging mechanisms:

Clinical Features

ICUAW typically manifests after 1–2 weeks of critical illness, though subclinical changes on electrophysiology may be detectable within days of ICU admission. The clinical presentation is often first recognized as difficulty weaning from mechanical ventilation or inability to participate in rehabilitation.

• Symmetric, flaccid limb weakness: Affects proximal and distal muscles; severity ranges from mild difficulty with antigravity movements to complete quadriplegia
• Failure to wean from ventilation: Diaphragmatic and respiratory muscle involvement is common and may be the presenting sign; phrenic neuropathy and diaphragmatic myopathy contribute
• Preserved facial and extraocular muscles: A distinguishing feature from Guillain-Barré syndrome; cranial nerve function is typically intact
• Reduced or absent deep tendon reflexes: Characteristic of CIP; reflexes may be relatively preserved in isolated CIM
• Sensory involvement: Clinically difficult to assess in sedated patients; CIP causes distal sensory loss (pain, temperature, vibration), while CIM has no sensory involvement
• Muscle wasting: Visible atrophy develops within 1–2 weeks, particularly in the quadriceps, tibialis anterior, and hand intrinsics; muscle mass loss of 1–1.5% per day occurs with immobility alone

Diagnosis

Clinical Assessment

The Medical Research Council (MRC) sum score is the standard bedside screening tool. Strength is graded (0–5) in six bilateral muscle groups (shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, ankle dorsiflexion) for a maximum score of 60. An MRC sum score <48/60 defines ICUAW, and <36/60 indicates severe ICUAW. Handgrip dynamometry provides an objective alternative; cutoffs of <11 kg in males and <7 kg in females correlate with ICUAW diagnosis. Both assessments require patient cooperation and alertness, limiting their utility in sedated or encephalopathic patients.

Electrodiagnostic Studies

NCS and EMG are essential to differentiate CIP from CIM and to exclude other diagnoses. The ICU environment presents technical challenges including limb edema, hypothermia, electrical interference, and patient cooperation.

Key diagnostic pearl: The presence of reduced SNAP amplitudes on NCS is the most reliable feature distinguishing CIP from CIM. However, technical factors in the ICU (edema, hypothermia) may produce falsely low SNAPs, so results must be interpreted cautiously.

Laboratory & Biopsy Findings

• Creatine kinase (CK): Mildly elevated (typically <10× ULN) or normal in CIM; normal in CIP. Markedly elevated CK should prompt consideration of rhabdomyolysis or necrotizing myopathy
• Muscle biopsy: The gold standard for CIM diagnosis; demonstrates selective loss of myosin heavy chains (thick filaments) on ATPase staining and electron microscopy, with preservation of thin (actin) filaments and Z-lines; type 2 fiber atrophy is common; inflammatory infiltrates are absent
• Nerve biopsy: Rarely performed; shows axonal degeneration without significant demyelination or inflammation in CIP
• Emerging biomarkers: Serum GDF-15 and IL-6 are under investigation for early detection; neuromuscular ultrasound showing reduced muscle thickness and increased echogenicity is a promising noninvasive tool

Prevention

Management

No pharmacologic therapy has demonstrated efficacy for treating established ICUAW. Management is predominantly supportive and rehabilitative:

• Rehabilitation: Progressive mobilization from passive range of motion to active exercise, including functional electrical stimulation (FES) and cycle ergometry; physical and occupational therapy should begin in the ICU and continue through post-ICU care
• Ventilator weaning: Protocolized weaning with spontaneous breathing trials; diaphragmatic ultrasound can guide assessment of respiratory muscle function; tracheostomy should be considered for patients requiring prolonged ventilation (>14–21 days)
• Nutritional support: Adequate caloric and protein delivery to support anabolic recovery; avoid overfeeding, which increases CO₂ production and may impair weaning
• Treatment of underlying conditions: Aggressive management of sepsis, correction of metabolic derangements, minimizing ongoing iatrogenic exposures
• Pain management: Neuropathic pain from CIP may require gabapentinoids or low-dose tricyclic antidepressants during recovery
• Follow-up: Serial NCS/EMG at 3–6 month intervals to track recovery; referral to neuromuscular clinic for persistent weakness beyond 6 months

Prognosis

Prognosis depends on the subtype, severity, and underlying comorbidities. Several key patterns have emerged from longitudinal studies:

Long-term follow-up studies demonstrate that while most patients recover walking ability, many experience chronic fatigue, reduced exercise tolerance, and psychological sequelae including anxiety, depression, and post-traumatic stress disorder (PTSD) as part of the post-intensive care syndrome (PICS).

References

1. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10(10):931–941.
2. Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19(1):274.
3. Fan E, Cheek F, Chlan L, et al. An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit-acquired weakness in adults. Am J Respir Crit Care Med. 2014;190(12):1437–1446.
4. Vanhorebeek I, Latronico N, Van den Berghe G. ICU-acquired weakness. Intensive Care Med. 2020;46(4):637–653.
5. Shepherd SJ, Newman R, Brett SJ, Griffith DM. Pharmacological therapy for the prevention and treatment of weakness after critical illness: a systematic review. Crit Care Med. 2016;44(6):1198–1205.
6. Stevens RD, Marshall SA, Engoren M, et al. Pathophysiology and management of critical illness polyneuropathy and myopathy. J Appl Physiol. 2021;130(5):1479–1489.
7. Z'Graggen WJ, Lin CS, Howard RS, Beale RJ, Bostock H. Nerve excitability changes in critical illness polyneuropathy. Brain. 2006;129(Pt 9):2461–2470.
8. Kramer CL. Intensive care unit-acquired weakness. Neurol Clin. 2017;35(4):723–736.
9. Friedrich O, Reid MB, Van den Berghe G, et al. The sick and the weak: neuropathies/myopathies in the critically ill. Physiol Rev. 2015;95(3):1025–1109.
10. Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310(15):1591–1600.
11. Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Muscle Nerve. 2000;23(12):1785–1788.
12. Koch S, Spuler S, Deja M, et al. Critical illness myopathy is frequent: accompanying neuropathy protracts ICU discharge. J Neurol Neurosurg Psychiatry. 2011;82(3):287–293.
13. Hermans G, Van Mechelen H, Bruyninckx F, et al. Predictive value for weakness and 1-year mortality of screening electrophysiology tests in the ICU. Intensive Care Med. 2015;41(12):2138–2148.
14. Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology. 2005;64(8):1348–1353.
15. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373(9678):1874–1882.
16. Mayer KP, Thompson Bastin ML, Montgomery-Yates AA, et al. Recovery and long-term functional outcome in people with critical illness polyneuropathy and myopathy: a scoping review. BMC Neurol. 2022;22(1):50.
17. Jolley SE, Bunnell AE, Hough CL. ICU-acquired weakness. Chest. 2016;150(5):1129–1140.
18. Weber-Carstens S, Koch S, Gress T, et al. Nonexcitable muscle membrane predicts intensive care unit-acquired paresis in mechanically ventilated, sedated patients. Crit Care Med. 2009;37(9):2632–2637.